Statins—taken by more than 25 million Americans to combat the high cholesterol levels that can harm cardiovascular health—are highly effective when it comes to lowering the risk for cardiovascular-related events and mortality. They also are low cost, and generally safe to take. However, for some people, statins come with side
Cholesterol-lowering statins are wonder drugs for reducing low-density lipoprotein (LDL, “bad”) cholesterol and lessening cardiovascular risk. Yet, a significant number of patients cannot tolerate the medications or fail to reach target LDL levels despite being on maximum-dose statin therapy.
Enter a new class of drugs—proprotein convertase subtilisin kexin type 9 (PCSK9)